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Summary 
The specificity of T lymphocyte activation is determined by engagement of the T cell receptor 
(TCR) by Peptide/major histocompatibility complexes expressed on the antigen-presenting cell 
(APC). Lacking costimulation by accessory molecules on the APC, T cell proliferation does not 
occur and unresponsiveness to subsequent antigenic stimulus is induced. The B7/BB1 receptor 
on APCs binds CD28 and CTLA-4 on T cells, and provides a costimulus for T cell proliferation. 
Here, we show that prolonged, specific T cell hyporesponsiveness to antigenic restimulation is 
achieved by blocking the interaction between CD28 and B7/BB1  in human mixed leukocyte 
culture (MLC).  Secondary T  cell proliferative responses to specific alloantigen were inhibited 
by addition to the primary culture of monovalent Fab fragments of anti-CD28 monoclonal antibody 
(mAb) 9.3, which block interaction of CD28 with B7/BB1 without activating T cells. Hypo- 
responsiveness was also induced in MLC by CTLA4Ig, a chimeric immunoglobulin fusion protein 
incorporating the extracellular domain of CTLA-4 with high binding avidity for B7/BB1. Cells 
previously primed could also be made hyporesponsive, if exposed to alloantigen in the presence 
of CTLA4Ig. Maximal hyporesponsiveness was achieved in MLC after 2 d of incubation with 
CTLA4Ig, and was maintained for at least 27 d after removal of CTLA4Ig. Accumulation of 
interleukin 2 (11.2) and interferon "y but not I1.4 mRNA was blocked by CTLA4Ig in T cells 
stimulated by alloantigen. Antigen-specific responses could be restored by addition of exogenous 
I1.2 at the time of the secondary stimulation. Addition to primary cultures of the intact bivalent 
anti-CD28 mAb 9.3, or B7/BB1 + transfected CHO cells or exogenous I~2, abrogated induction 
of hyporesponsiveness by CTLA4Ig. These data indicate that interaction of CD28 with B7/BB1 
during TCR engagement with antigen is required to maintain T cell competence and that blocking 
such interaction can result in a state of T  cell hyporesponsiveness. 
E 
ffective presentation of antigen to T cells requires a com- 
plex series of events to initiate the immune response. In 
addition to processing and presenting antigenic Peptides in 
the context of MHC molecules to specific  TCRs, APCs must 
provide one or more costimulatory signal(s) to fully activate 
T  cells, and induce II-2 release and DNA synthesis (1-7). 
In the absence of costimulatory signals, T cells presented with 
antigen may enter a state of anergy characterized by the failure 
to activate the I1.2 gene in response to further antigenic stim- 
ulation (4). In certain instances, lack of costimulation may 
lead to activation-driven  cell death (8). Binding of surface 
receptors on T  cells to their natural ligands,  such as CD2 
to LFA-3 (9), CD4 to MHC dass II (9), LFA-1 to intercel- 
hlar adhesion molecule 1 (ICAM-1) or ICAM-2 (10), and 
CD28 to B7/BB1  (11) have been implicated in facilitating 
T cell-APC interactions and inducing T cell activation. CD28 
signaling  stimulates  cytokine production by  T  cells, by 
regulating gene transcription and also by stabilizing mRNAs 
(12-16). Binding of CD28 to the B7/BB1 counter receptor 
costimulates I1.2 mRNA accumulation and T cell prolifera- 
tion (17-20).  CD28-mediated signaling prevents induction 
of anergy in murine T  cell clones (21). 
CTLA-4,  a  molecule homologous to  CD28  originally 
identified by screening of a murine cytolytic T cell cDNA 
library (22), also binds to B7/BB1 (23). Studies of the binding 
properties of CTLA-4 and B7/BB1 were facilitated by con- 
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lular domain of CTLA-4 and an IgG 71 chain (23). CTLA4Ig 
has a high avidity for the B7/BB1 molecule (Kd --12 nM) 
and is a potent inhibitor of immune responses  in vitro and 
in vivo (23-25). 
In this study, we have investigated the role of CD28 inter- 
actions with B7/BB1 in providing the costimulation neces- 
sary to maintain proliferative competence of human T cells. 
We have found that blocking the interaction of CD28 with 
BT/BB1 either by anti-CD28 mAb 9.3 Fab fragments or by 
CTLA4Ig when T cells are presented with alloantigen in a 
mixed leukocyte culture (MLC)  1 leads  to  sustained T  cell 
hyporesponsiveness  to the specific alloantigen. 
Materials and Methods 
Ig Fusion Proteins, mAbs, and Transfected Cell Lines.  CTLA4Ig 
was produced by CHO cells transfected  with the CTLA4Ig eDNA 
expression construct and was purified as described previously (23). 
Purified human mouse chimeric mAb L6 was a gift of Ingegerd 
and Karl Erik HeUstrom  (Bristol-Myers  Squibb Pharmaceutical  Re- 
search Institute,  Seattle, VIA). Murine mAbs 9.3  (anti-CD28, 
IgG2a), BB1 (anti-BT/BB1 antigen, IgM), 9E8 (anti-p15E, IgG2a), 
and T11D7, (anti-Thyl.1, IgM, kind gift of Irwin Bernstein, Fred 
Hutchinson Cancer Research Center) have been described previ- 
ously and were purified from aseites before use (26-28). Prepara- 
tion of Fab fragment of mAb 9.3 has been described previously 
(29). B7 + CHO cells have been previously described (23) and 
CD5 + CHO cells were constructed as described (19, 23) using an 
expressible CD5 eDNA provided by Dr. A. Aruffo (Bristol-Myers 
Squibb Pharmaceutical Research Institute). 
Primary MLC.  PBMC were prepared by density gradient cen- 
trifugation  on Ficoll-Hypaque. The cells were resuspended in 
medium containing RPMI 1640, 25 mM Hepes, 1 U/ml penicillin, 
1/~g/ml streptomycin, and 15% pooled human serum that had 
been heat inactivated at 56~  for 30 rain. As indicated for certain 
experiments, T cell subsets were purified  by negative  selection  using 
complement-dependent lysis and panning (30). Responders and 
stimulators were unrelated individuals chosen so that there was 
at least one HLA class I and one HLA-DR antigen mismatched 
within each pair. 5  x  104 responder cells were mixed with 5  x 
104 irradiated stimulator cells (3,000 rad) in round-bottomed 96- 
well plates. These were incubated at  37~  in a 5%  COz at- 
mosphere. Assays  were performed  in triplicate. Cultures were pulsed 
with one/~Ci of [3H]thymidine 18 h before harvesting. 10 repli- 
cate plates were set up and one was harvested each day for 10 con- 
secutive d. Data are reported as mean cpm of the three replicates. 
In selected  experiments, readings were taken on day 6 of the MLC. 
Restimulation Assays.  107  PBMC from  one individual were 
primed with an equivalent number of  irradiated (3,000 tad) PBMC 
from another HLA class I- and II-incompatibh individual in 25 
cm  2 flasks, using identical culture conditions as for primary MLC 
carried out in 96-well plates. For blocking experiments, cells were 
cultured for 7 d in the presence of human Ig fusion proteins 
CTLA4Ig or human-mouse chimeric mAb L6, used as control. 
Then cells  were washed three times, re~tured in medium without 
Ig for an additional 3 d, harvested on day 10, and then restimu- 
lated. Primed cells were restimulated with fresh stimulator cells 
1  Abbreviations  used in this  paper: CTLp, cytolytic  precursor; MI/2, mixed 
leukocyte culture. 
from the original  donor or from an unrelated  donor. The two donors 
did not share HLA-DR, DOs or DP antigens. In experiments of 
tertiary stimulation, a secondary culture was carried out in flask, 
as in the first. As indicated in certain experiments, alloantigen- 
primed CD4 + T cell lines were generated by stimulation with 
cells from an EBV-transformed B line from an unrelated donor. 
For the assay, 2  x  104 primed responders and 5  x  104 irradiated 
stimulators were incubated in 96-well round-bottomed wells in 
medium without any Ig fusion protein. Assays  were performed as 
detailed for primary MLC. 
Generation of CTL.  Fresh  PBMC or primed cells were tested 
for CTL precursor activity by priming in MLC. Responder cells 
(107  ) either fresh or primed as specified  for each experiment, and 
irradiated stimulators (107), were cultured  for  6 d,  harvested, 
washed twice, and tested for cytolytic effector activity in a 4-h 
SlCr-release assay against PHA blasts. Both autologous or stimu- 
lator cells were tested as target cells. Maximum and spontaneous 
release values  were obtained by incubating targets with 1% Triton 
X-100 and medium alone, respectively. Triplicate assays  were car- 
ried out at E/T ratios of 25:1, 50:1, and 100:1 in V-bottomed 96- 
well plates. Data are reported as mean percent specific  5~Cr-release. 
RNA Blot Analysis.  RNA was prepared from T cells ("~1-3 
x  107Aample)  by a rapid isolation procedure (31). RNA (10 #g) 
was fiactionated  on formaldehyde  agarose  gels, transferred  and cross- 
linked to Zetaprobe membranes (Bio-Rad  Laboratories,  Cambridge, 
MA). Probes for IL-2, II,4, IFN-3, and glyceraldehyde-6-phosphate 
dehy&ogenase (GAPDH) have been previously described (19, 32, 
33). DNA fragments were purified and labeled with 3zp using a 
random priming kit (Boehringer Mannheim Corp., Indianapolis, 
IN). The prehybridized membranes were sequentially hybridized 
with different 3zP-labeled probes. Between hybridizations, each 
probe was stripped from the blots by boiling in a solution of SSC 
(0.15 M NaC1, 0.015 M sodium citrate) containing 0.1% SDS. 
Results 
Induction of Antigen-specific Hyporesponsiveness by Fab Fra  e- 
menu of Anti-CD28 mAb 9.3.  Monovalent Fab fragments 
of the anti-CD28 mAb 9.3 can block T cell proliferative re- 
sponses to alloantigen in primary MLC, by preventing the 
interaction of CD28 with its natural ligand BT/BB1 expressed 
on APCs (12). To evaluate whether there is a long-lasting 
effect of blocking the CD28 receptor during the initial ex- 
posure to antigen, we performed restimulation experiments. 
Lymphocytes  were cultured with alloantigen for 7 d in sepa- 
rate flasks in medium containing 5 ~g/ml Fab of 9.3 mAb 
or control mAb. Cells were then washed to remove mAb, 
cultured in fresh medium for an additional 3 d, and then re- 
stimulated with irradiated PBMC from either the original 
donor (Fig. 1, left) or from a third party donor (Fig. 1, right) 
in medium without mAb. Cells primed in the presence  of 
control mAb and restimulated with PBMC originaUy used 
for priming showed a typical accelerated secondary prolifera- 
tive response peaking on day 3. In contrast, those same primed 
cells showed a typical primary response,  peaking on day 6, 
when stimulated with PBMC from a third party donor. Ceils 
primed in the presence  of 9.3 Fab, however,  showed a de- 
creased  response when challenged with PBMC from the 
original donor, yet responded normally to PBMC from a third 
party donor. These results demonstrate that the secondary 
proliferative response of human T  ceUs can be inhibited in 
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Figure  1.  Fab fragments of anti-CD28 mAb 9.3 induce 
T cell  hyporesponsiveness  in MLC. For the secondary  MLR, 
responders from a normal individual were primed with cells 
from an HLA-incompatible  donor  in the presence  of  9.3 mAb 
lab (triangle)  or control (square). Cells  were  restimulated  from 
the original donor (left) or a third party donor (right)  in the 
absence of mAb. Cells primed in the absence  of mAb were 
restimulated against autologous  cells  to define  the background 
for the assay (*). 
an antigen-specific manner by blocking CD28 during the pri- 
mary exposure to alloantigen. 
Inhibition ofT CelI  Responses  to Alloana'gen by CTLA4I~  To 
determine whether antigen-specific hyporesponsiveness could 
also be induced by blocking B7/BB1, the natural ligand for 
CD28 expressed on APC, further experiments evaluated the 
activity of CTLA4Ig, a fusion protein with high affinity for 
B7/BB1. Both responder and irradiated stimulator cells were 
preincubated with CTLA4Ig or control Ig for 30 min at 37~ 
before mixing. CTLA4Ig inhibited primary alloproliferative 
responses by 50-85%,  and maximal inhibition  was seen at 
or above 2.5 gg/ml of CTLA4Ig (data not shown), consis- 
tent with previous findings (23).  mAb BB1 (26),  a murine 
IgM antibody that binds to the B7/BB1 antigen with lower 
avidity than CTLA4Ig (23) inhibited MLR by only '~30%. 
Thus,  CTLA4Ig  inhibited  primary  T  cell responses more 
efficiently than mAb BB1, although the inhibition  achieved 
was not  complete. 
Previous studies had shown that  CD4+/CD28 + T  cells 
constitute 95-99.5%  of CD4 + peripheral blood T  cells and 
proliferate vigorously to HLA class II determinants in MLR 
(34),  whereas CD4+/CD28 -  T  cells  constitute 0.5-5.0% 
of all CD4 + T  cells and respond poorly in MLR (35),  and 
CD8 + T  cells do not proliferate at all in human MLR.  By 
flow microfluorimetric  analysis  we found that  CD4 + cells 
constituted 79% of viable lymphocytes on day 6 of an MLR 
carried out in the presence of control Ig compared with 56% 
in the presence of CTLA4Ig,  and CD28 + cells constituted 
72% of viable lymphocytes after an MLR carried out in the 
presence of control Ig compared with 56% in the presence 
of CTLA4Ig.  Thus,  CTLA4Ig blocked the increase in the 
proportion of CD4 + and CD28 + cells during MLR.  Since 
requirements for proliferation are more stringent in naive than 
in memory cells,  one expected MLR response of naive cells 
to be more susceptible to inhibition by CTLA4Ig than MLR 
response  of memory  cells.  CD4 +/CD45RA +  (naive)  and 
CD4+/CD45RO +  (memory)  T  cell subsets were purified 
by negative selection, through panning  of PBMC obtained 
from adult volunteers,  and tested in MLR. CTLA4Ig inhibited 
thymidine  uptake of CD4+/CD45RA + cells by 84%  and 
CD4+/CD45RO + cells  by 74%.  As an  alternative  source 
of naive T  cells, mononudear cells were obtained from um- 
bilical cord blood and tested in MLR.  CTLA4Ig inhibited 
thymidine uptake of cord blood cells stimulated by irradiated 
PBMC obtained from an unrelated adult by 78%. These results 
indicate that CTLA4Ig can inhibit proliferative responses to 
HLA class II determinants in either naive or memory T cells 
with the CD4 + and CD28 + phenotype. However, in no T 
cell subset analyzed was the inhibition  complete. 
Effect of CTLA4Ig on Lymphokine Production.  Prolifera- 
tive T cell responses to alloantigen occurring despite the pres- 
ence of CTLA4Ig might  not be driven by Ib2, but rather 
by Ib4. Steady state message for IL-2, Ib4, and IFN-3' was 
measured in mKNA  prepared  from proliferative CD4 + T 
cell lines  stimulated by specific  alloantigen  in the presence 
or absence of CTLA4Ig (Fig. 2). Transcripts for Ib2 and IFN-,y 
were lower in mKNA from ceils  cultured with CTLA4Ig 
compared with control cells. In contrast, transcripts for Ib4 
peaked at 4 h after stimulation and were detected at similar 
levels  in  mRNA  from  cells  cultured  with  or  without 
CTLA4Ig. Thus, IL2 and IFN-3' transcripts  do not accumulate 
in T cells stimulated by alloantigen when B7/BB1 is blocked 
by CTLA4Ig, whereas IL-4 transcripts do accumulate. There- 
fore, IL-4 could drive antigen-specific T cell proliferation  which 
occurs despite blocking by CTLA4Ig. 
Induction of  Antigen-specific  Hyporesponsiveness  by CTLA 4Ig. 
To evaluate the effect of CTLA4Ig on secondary responses, 
Figure 2.  Regulation  of  lymphokine transcripts by CTLA4Ig. Resting 
alloantigen-primed CD4  + T cells (2 x  107)  were collected  and restimu- 
lated with irradiated lymphoblastoid  cells. Cells were harvested at the in- 
dicated times, RNA was extracted  and analyzed  by blot analysis. The blot 
was sequentially  hybridized  with 32p-labeled  probes  for IL-2, Ib4, IFN-'y 
and GAPDH, as described  in Material and Methods. Migration positions 
are noted  of  the 28S and 18S ribosomal  RNA species  visualized  by ethidium 
bromide staining. 
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containing 5 #g/ml CTLA4Ig or control Ig. Cells were then 
washed to remove Ig, cultured in fresh medium for an addi- 
tional 3 d, and then restimulated with irradiated PBMC from 
either the original donor (Fig.  3, top left) or from a third 
party donor (Fig. 3, bottom left) in medium without Ig. Cells 
primed in the presence of CTLA4Ig showed a decreased re- 
sponse when challenged with PBMC from the original donor, 
yet responded normally to PBMC from a third party donor. 
Flow microfluorimetric analysis of CD4 + cells on day 3 of 
the secondary cultures indicated that expression of the II.-2 
receptor o~ chain (CD25) was lower in CTLA4Ig-treated cul- 
tures than in controls (data not  shown).  Antigen-specific 
hyporesponsiveness was achieved with as low as 1 #g/ml of 
CTLA4Ig in the priming culture, but there was no effect 
on responsiveness to third party donors even at a CTLA4Ig 
concentration of 10 #g/ml (data not shown). Hyporespon- 
siveness was demonstrated in cells cultured with alloantigen 
in the presence of CTLA4Ig for 7 d, and then rested in medium 
alone for 20 d and 27 d after initiation of the culture (Fig. 
3). In six experiments using different pairs of responder and 
stimulator cells, primary MLC in the presence of CTLA4Ig 
inhibited the secondary proliferative responses to the specific 
alloantigens by an average (+SD) of 70 _+  13%, whereas re- 
sponses to third party donors were unaffected (4 _+ 3% inhi- 
bition). Secondary proliferative responses to specific aUoan- 
tigen were inhibited by an identical degree, if the primary 
cultures were carried out in the presence of either CTLA4Ig 
(84% inhibition) or anti-CD28 mAb Fab (83% inhibition), 
but no greater inhibition was achieved by a combination of 
the two (84%  inhibition).  These results demonstrate that 
secondary proliferative responses can be specifically inhibited 
by primary exposure of T cells to alloantigen in the presence 
of either anti-CD28 mAb Fab fragments or CTLA4Ig, and 
are consistent with the model that both agents block the same 
pathway of T  cell activation. 
Effect  of CTLA4Ig  on  Responsiveness of Primed  Cells. 
Further experiments were designed to determine whether 
alloantigen-specific hyporesponsiveness could be induced by 
CTLA4Ig in primed calls. Cells were primed to alloantigen 
in medium without CTLA4Ig or control for 10 d  (Fig.  4, 
top left). CeUs were then washed and restimulated with ir- 
radiated cells from the original donor. Both responder and 
stimulator cells were incubated with CTLA4Ig or control 
Ig for 30 rain at 37~  before mixing. The secondary prolifer- 
ative response was inhibited by CTLA4Ig compared with the 
Ig control (Fig.  4, top right). In separate cultures set up in 
flasks, primed cells were restimulated with PBMC from the 
original donor in the presence of CTLA4Ig or control Ig 
for 7 d, washed to remove the Ig, and rested in medium for 
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Figure 3.  CTLA4Ig  induces antigen-specific  hyporesponsiveness  in unprimed  cells. Responders  from a normal individual were primed with cells 
from an HLA-incompatible  donor in the presence  of CTLA4Ig (tr/ang/e)  or control Ig (square).  At the indicated  time points, primed  cells were  restimu- 
lated from the original donor (top) or a third party donor (bottom) in the absence of Ig. CeUs primed  in the absence of Ig were restimulated  against 
autologous cells to define the background for the assay (*). 
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Figure 4.  CTLA4Ig induces antigen-specific hyporesponsiveness in 
primed cells. PBMC were primed with allogeneic stimulators (square) in 
absence of Ig (top left; [*] autoiogous stimulation). Primed ceils  were res- 
timulated in secondary  MLIL  with cells  from the original donor (top right) 
in the presence of CTLA4Ig (triangle) or control Ig (square). Cells from 
the respective cultures were washed and then restimulated in a tertiary 
MLR (bottom) with calls from the original donor (/eft) or a third party 
donor (right) in absence  of Ig. Cells primed in the absence of Ig were res- 
timulated against autologous  ceils  to define  the background  for the assay  (*). 
an additional 3 d. They were then stimulated again in a ter- 
tiary culture with specific or third party alloantigen.  Cells 
preincubated with control Ig exhibit a typical anamnestic re- 
sponse when restimulated with ceils from the original donor. 
In contrast, cells preincubated with CTLA4Ig showed a di- 
minished response to cells from the original donor (Fig. 4, 
bottom/eft),  whereas their response to a third party donor 
was unaffected (Fig. 4, bottom right).  These findings indicate 
that primed ceils can also become hyporesponsive if exposed 
to alloantigen  in the presence of CTLA4Ig. 
Kinetics of Induction of Hyporesponsiveness  by CTLA 4Ig.  To 
determine the duration of exposure to CTLA4Ig necessary 
for development of hyporesponsiveness, ceils were washed on 
days 1, 2, or 3 of primary MLC, resuspended in fresh medium 
without Ig, and rested until day 10 when they were restimu- 
lated with irradiated PBMC from the original donor or from 
a third party donor. Primary MLC in the presence of CTLA4Ig 
for 2 or 3 d inhibited the secondary response to the original 
donor >80%, but had no effect on the response to third party 
donors. Primary MLC in the presence of CTLA4Ig for 1 d 
inhibited the secondary response to the original donor by only 
~15%.  Therefore, maximum  induction of antigen-spedfic 
hyporesponsiveness is achieved in MLC after 2 d of incuba- 
tion  with  CTLA4Ig. 
Effect of lL2 on Hyporesponsive  Cells.  Hyporesponsiveness 
in secondary MLR could be due to the death of antigen-specific 
T cells occurring during the primary culture or to the acqui- 
sition of a defect in one of the cellular functions that limits 
the rate of ceil proliferation,  such as IL-2 production. Addi- 
tion of exogenous II~2 to secondary cultures could help de- 
termine whether Ib2-responsivr  antigen-specific T ceils were 
still alive. Primary MLCs were set up in medium containing 
CTLA4Ig or control Ig. When challenged with PBMC from 
the original donor, cells primed in the presence of CTLA4Ig 
showed a lower response (Fig.  5, center)  than calls  primed 
in the presence of control Ig (Fig. 5,/eft), yet responded equally 
well to PBMC from a third party donor.  Exogenous rIL-2 
added at 10 IU/ml to secondary cnltures restored responsive- 
ness to specific  alloantigen  of cells primed in the presence 
of CTLA4Ig (Fig. 5, right).  These results indicate that pre- 
sentation of antigen while blocking interaction of CD28 with 
B7/BB1 can induce a state of T  cell hyporesponsiveness to 
antigen  which can be corrected by exogenous IL-2. 
Effe, of iZ.2 o, x,a tio,  of A.tig n-spec6c H ,orespo si e- 
hess by CTLA4Ig.  CD28 signaling concurrent with TCR 
engagement results in IL-2 secretion, T  cell activation and 
proliferation.  Therefore, we tested whether exogenous IL-2 
could provide T cells with a signal that could bypass the block 
provided by CTLA4Ig in the primary MLC and prevent in- 
duction of antigen-specific  hyporesponsiveness.  Primary MLCs 
were set up with CTLA4Ig, with or without riD2 at 10 IU/rnl 
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Figure 5.  Exogenous  IL-2 restore responsiveness to specific  antigen. Cells were primed to alloantigen in the presence  of control Ig (/eft) or CTLA4Ig 
(center and right). Primed cells were restimulated with autologous ceils (*), ceils from the original donor (square) or a third party donor (triangle) in 
the absence of Ig. Ceils primed in the presence of CTLA4Ig were restimulated in medium (center) or 10/~ rib2 (right). 
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Figure 6.  Exogenous II.-2 prevents induction of antigen- 
specific hyporesponsiveness by CTLA4Ig. Cells were primed 
in the presence of CTLA4Ig (triang/e), or control Ig (square), 
or CTLA4Ig plus IL-2 (cross). Primed cells were restimulated 
with cells form the original donor (/eft) or a third party donor 
(right) in the absence of Ig or II22. Cells primed in the ab- 
sence of Ig were restimulated against autologous ceUs to define 
the background for the assay (*). 
added at the initiation of the culture or control Ig. Cells primed 
in the presence of CTLA4Ig alone showed hyporesponsive- 
ness when restimulated with the specific alloantigen (Fig. 
6, left). However, cells primed in the presence of CTLA4Ig 
plus rlL-2 showed the same degree of secondary response to 
the  specific  stimulators  as  ceils  primed  in  the  presence  of  control 
Ig.  Neither  CTLA41g nor  rIL-2  affected  secondary  responses 
to  cells  from third  party  donors (Fig.  6, right).  These results 
indicate  that  antigen-specific  hyporesponsiveness  induced  by 
priming T cells  in the presence  of CTLA41g in MI.C can 
beprevented by stimulation  with exogenous IL-2. 
Effect of  Anti-CD28 mA b 9.3 or Cell-bound B7/BB1 Receptor 
on Induction of  Antigen-specific 8yporesponsiveness by CTLA 4 I  g. 
In contrast to monovalent Fab fragments of anti-CD28 mAb 
9.3, the bivalent intact mAb 9.3 can crossllnk CD28 mole- 
cules and activate T cells efficiently (29). Therefore, we tested 
whether the intact mAb 9.3 could deliver a signal to T cells 
and prevent induction of hyporesponsiveness by CTLA4Ig. 
Primary MLCs were set up with CTLA4Ig with or without 
mAb 9.3 or controls. Cells primed in the presence of CTLA4Ig 
alone showed hyporesponsiveness, compam:l with cells primed 
in the presence of control Ig alone (not shown) or control 
Ig plus mAb 9.3, when restimulated with the specific allo- 
antigen (Fig. 7, left). However, cells primed in the presence 
of CTLA4Ig plus mAb 9.3 showed the same degree of sec- 
ondary response to the specific stimulators as was shown by 
cells primed in the presence of control Ig and mAb 9.3. Nei- 
ther CTLA4Ig nor mAb 9.3 affected secondary responses to 
cells from third party donors (Fig.  7, right). 
Further experiments tested the effect of exogenous B7/BB1 
antigen expressed on transfected CHO cells. Irradiated (104 
rad) B7 + CHO cells (19) were mixed with fresh responder 
PBMC at a ratio of 1:100, before addition of CTLA4Ig or 
control Ig and irradiated stimulator PBMC. MLC without 
CHO cells but with CTLA4Ig or control Ig alone were set 
up in parallel. Cells primed in the presence of CTLA4Ig alone 
showed hyporesponsiveness to specific alloantigen when com- 
pared with cells primed in the presence of control Ig. Cells 
primed in the presence of CTLA4Ig and the negative con- 
trol CD5 + CHO cells also showed hyporesponsiveness.  In 
contrast, cells primed in the presence of CTLA4Ig and B7 + 
CHO cells showed the same degree of secondary response 
to the specific stimulators, as was shown by cells primed in 
the presence of control Ig and no CTLA4Ig (data not shown). 
Neither CTLA4Ig nor transfected  CHO cells affected sec- 
ondary responses to cells from third party donors (data not 
shown). These results indicate that antigen-specific  hypo- 
responsiveness induced by priming T  cells in the presence 
of CTLA4Ig in MLC can be prevented by stimulating CD28 
with mAb 9.3 or with the natural ligand B7/BB1. 
Effect of CTLA4Ig on CTL Generation.  CTLA4Ig did not 
inhibit the effector phase of the cytolytic reaction by acti- 
vated CTL against allogeneic target T  cell blasts  (data not 
shown). To determine whether CTLA4Ig added to the pri- 
mary MLC could block the generation of CTL activity, MLCs 
were set up in medium containing CTLA4Ig or control Ig 
for 5 d. Cells primed in the presence of CTLA4Ig showed 
a fourfold decreasein cytolytic activity against allogendc target 
T cell blasts when compared with cells primed in the pres- 
ence of control Ig (data not shown). To determine whether 
the block in the generation of CTL activity by CTLA4Ig 
was  specific, MLCs  were  set  up  in  medium containing 
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CPM (Thousands) 
.'/  ,~  . 
1  2  3  4  $  6  7 
TIME IN DAYS 
Third Party Antigen 





'  o  9 
C.ormol  Ig +  9,3 
~"  CTLA  4  Ig +  9.3 
~,  , 
1  2  3  4  5  6  7  8  9 
TIME IN DAYS 
Figure 7.  Intact mAb 9.3  blocks induction of antigen- 
specific hyporesponsiveness by CTLA4Ig. Cells were primed 
in the presence of CTLA4Ig (tr/angk), or control Ig plus mAb 
9.3 (square), or CTLA4Ig plus mAb 9.3 (cross). Primed lym- 
phocytes were restimulated with cells from the original donor 
(left) or a third party donor (right) in the absence of Ig. Cells 
primed in the absence of Ig were restimulated against autolo- 
gous cells to define the background for the assay (*). This 
experiment is representative of two other experiments of similar 
design that achieved identical results. 
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tured in fresh medium without CTLA4Ig for 3 d. Cells were 
then restimulated with irradiated PBMC from the original 
donor or from a third party donor for 3 d and then tested 
for cytolytic activity. Cells previously primed in the presence 
of CTLA4Ig again showed a fourfold decrease in cytolytic 
activity against specific alloantigen (Fig. 8, left) when com- 
pared with cells primed in the presence of control Ig. In con- 
trast, cells previously cultured in the presence of CTLA4Ig 
were able to generate cytotoxic activity against a third party 
donor to the same degree as cells cultured with control Ig 
(Fig. 8, right).  Thus, CTLA4Ig inhibited the generation of 
specific CTL. 
Discussion 
Our study demonstrates that long-lasting, antigen-specific 
hyporesponsiveness can be induced in T cells by exposure to 
alloantigen while blocking the interaction of CD28 on T 
cells with B7/BB1 on allogeneic APC. Effective  blockade could 
be achieved  using either monovalent anti-CD28 mAb 9.3 frag- 
ments or CTLA4Ig, a soluble recombinant fusion product 
of human CTLA-4 and IgG 3'1 chain, the binds to B7/BB1 
with high avidity. Previous reports had shown that anti-CD28 
mAbs augment proliferation of human T  cells in the pres- 
ence of specific antigen and defective APCs (16). Further work 
showed that interaction of CD28 with B7/BB1 provides a 
costimulatory signal for T cell activation (17-20). Data from 
Schwartz and other investigators (4-7, 36) indicated that in 
the absence of costimulatory signals provided by the APC, 
T cells encountering specific antigen enter a state of anergy 
characterized  by an I1:2 production defect. Harding et al. 
(21) demonstrated that CD28 signaling can prevent anergy 
in murine T  cell clones.  Our data are consistent with the 
model that the CD28-B7/BB1  interaction can provide a 
costimulus required for T cell activation. CD28 ligation is 
required for I1:2 gene activation in antigen-specific responses. 
Blocking CD28 ligation by either 9.3 mAb Fab or CTLA4Ig 
may inhibit  II.-2 expression and  elicit  a  state  of T  cell 
hyporesponsiveness. 
Human MLR experiments allowed us to study the require- 
ments for antigen-specific responses of CD4 +/CD28 + cells, 
since proliferation of CD4 +/CD28-  cells and CD8 + cells 
cannot be detected in this model system. CTLA4Ig blocked 
proliferation of CD4+/CD28 + in primary MLC and achieved 
a similar degree of inhibition in naive and memory T cells. 
A state of antigen-specific  hyporesponsiveness  could be induced 
by CTLA4Ig in primed as well as in unprimed cells. Secondary 
proliferative  responses  to the specific alloantigen were de- 
creased, but not abolished by the presence of either anti-CD28 
mAb 9.3 lab or CTLA4Ig in primary cultures. Residual T 
cell responsiveness hardly could be explained by incomplete 
blocking of the CD28 or B7/BB1 receptors, since anti-CD28 
mAb Fab and CTLA4Ig used together did not demonstrate 
additive inhibitory activity. T cell proliferation could be in- 
duced through CD28-independent activation pathways ini- 
tiated by other accessory receptors, such as ICAM-1 (10). The 
heat-stable  antigen also functions as a costimulatory mole- 
cule and regulates T cell responsiveness  (37). CTLA4Ig blocked 
antigen-mediated activation of I1:2 and IFN-3` expression, 
but did not block I1:4 expression. Thus, 11,4 might be respon- 
sible for driving T cell proliferation in primary or secondary 
MLR. Further experiments will need to address whether neu- 
tralization of I1:4 in culture can achieve complete T cell un- 
responsiveness in this model. 
Exogenous IL-2 could restore antigen-specific proliferative 
responses in secondary cultures, suggesting that hyporespon- 
siveness was not the result of T cell death but, instead, was 
likely the result of an acquired T cell defect in II:2 produc- 
tion. Whether blocking alloantigen-mediated T cell activa- 
tion by CTLA4Ig can induce a sustained defect in II:2 produc- 
tion remains to be verified.  Exogenous I1:2  added at the 
beginning of the primary MLC prevented induction of antigen- 
specific hyporesponsiveness by CTLA4Ig in this study. This 
finding contrasts with the observation in the model using 
murine T cell clones stimulated in absence of accessory cells, 
where exogenous I1:2 cannot prevent hyporesponsiveness. As 
opposed to the murine model, MLK cultures contain acces- 
sory cells and with them an indefinite number of stimuli that 
could make less stringent the requirements for T cell activation. 
Both CD28 and CTLA-4 are natural ligands for B7/BB1, 
a receptor expressed on activated B lymphocytes and other 
APCs (38-41). Once expressed, B7/BB1 interacts with CD28 
and CTLA-4 to provide a stimulus for T cell activation (18, 
42).  The time required for B7 expression,  16-24 h after B 
cell activation (39), can explain why T cell hyporesponsive- 
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Figure 8.  CTLA4Ig  inhibits  CTL genera- 
tion. Responder  cells were  primed  in the pres- 
ence of CTLA4Ig (*) or control Ig (cross). 
Primed  cells  were  restimulated  with cells  from 
the original donor (left) or from a third party 
donor (right) in the absence of Ig and cytotcndc 
activity was assayed on day 3 of the secondary 
cultures against PHA stimulated T  lympho- 
blasts from the respective donors. Lysis of an- 
tologous targets (square)  by cells primed in ab- 
sence of Ig define the background for the assay. 
This experiment is representative of two other 
e~periments of similar design that achieved 
identical results. 
171  Tan et al. ness is not completely achieved in MLC by 24 h but requires 
48 h of incubation with CTLA4Ig.  CD28 ligation by the 
whole  anti-CD28  mAb  9.3  could  prevent  induction  of 
hyporesponsiveness by CTLA4Ig in MLC. Hyporesponsive- 
ness was also prevented by mixing irradiated B7 + CHO cells 
with responder lymphocytes at  the initiation  of the MLC 
before adding CTLA4Ig.  Prevention of hyporesponsiveness 
by B7 + CHO cells  may be achieved by direct stimulation 
of T  cells  through  CD28  or by neutralization  of soluble 
CTLA4Ig. We favor the former hypothesis since B7 + CHO 
cells were used at a very low frequency in the culture (1:100:100, 
B7 +  CHO  cells/responders/stimulators).  Under  these  ex- 
perimental conditions, we calculated that the concentration 
of CTLA4Ig in the culture exceeded the concentration  of 
the B7/BB1 receptor on the surface of CHO cells by at least 
100-fold on a molar basis. Thus, it was unlikely that CTLA4Ig 
could be neutralized  by B7 +  CHO cells.  The role of the 
CTLA-4 receptor in the achievement of T  cell hyporespon- 
siveuess has not been addressed directly in our studies. How- 
ever, since blocking CD28 by 9.3 mAb Fabs induced a level 
of hyporesponsiveness comparable to blocking B7/BB1 by 
CTLA4Ig, and since triggering CD28 by the intact 9.3 mAb 
could completely overcome hyporesponsiveness induced by 
CTLA4Ig,  it is unlikely that  signaling  by CTLA-4 per se 
is of major importance  in regulating  T  cell responses. 
CTLA4Ig not only blocked primary and secondary prolifer- 
ative  responses  but  also  blocked  activation  of  cytolytic 
precursors (CTLp). Cells exposed to alloantigeu in the pres- 
ence of CTLA4Ig were found to generate markedly dimin- 
ished  specific  cytolytic activity. These results  suggest that 
generation of cytolytic activity in the primary culture in the 
presence of CTLA4Ig was an unlikely explanation  for the 
hyporesponsiveuess in secondary culture. Recent findings in- 
dicate that  CD28 interaction  with B7/BB1 can amplify T 
cell-mediated cytolysis at the effector phase (43). In our ex- 
periments, however, there was no interference of CTLA4Ig 
at the lytic stage, probably because activated T  cell targets 
do not express B7/BB1. It remains to be determined whether 
CTLA4Ig blocked CTLp activation directly or indirectly by 
inhibiting  Th cell functions. 
Defining  the role of the interaction  between CD28 and 
B7/BB1 and between other T  cell accessory receptors and 
their natural ligands will help understand  the mechanisms 
for self-tolerance,  propose new strategies to manipulate the 
immune response, and achieve transplantation tolerance (24, 
25,  44). 
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